| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.13 | 0.004 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.085 | 0.06 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.083 | 0.07 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.08 | 0.07 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.08 | 0.08 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.063 | 0.2 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.048 | 0.3 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.052 | 0.3 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.049 | 0.3 |